These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 17921538)
1. [Side effects of the combined antiviral therapy in patients with chronic hepatitis C]. Vashakidze ET; Gegeshidze TN; Zhamutashvili MT; Svanidze MB Georgian Med News; 2007; (148-149):26-8. PubMed ID: 17921538 [TBL] [Abstract][Full Text] [Related]
2. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Demirturk N; Aykin N; Demirdal T; Cevik F Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483 [No Abstract] [Full Text] [Related]
3. Peginterferon and ribavirin for chronic hepatitis C. Hoofnagle JH; Seeff LB N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366 [No Abstract] [Full Text] [Related]
4. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C. Rogers CJ; Romagosa R; Vincek V J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524 [No Abstract] [Full Text] [Related]
5. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. Neri S; Bertino G; Petralia A; Giancarlo C; Rizzotto A; Calvagno GS; Mauceri B; Abate G; Boemi P; Di Pino A; Ignaccolo L; Vadalà G; Misseri M; Maiorca D; Mastrosimone G; Judica A; Palermo F J Clin Gastroenterol; 2010 Oct; 44(9):e210-7. PubMed ID: 20838237 [TBL] [Abstract][Full Text] [Related]
6. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C]. Lee YN; Jeong SW; Lim JH; Ryu YS; Jeon SR; Kim SK; Jang JY; Kim YS; Kim BS; Roh MO Korean J Hepatol; 2010 Jun; 16(2):187-91. PubMed ID: 20606504 [TBL] [Abstract][Full Text] [Related]
7. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Fontana RJ; Bieliauskas LA; Lindsay KL; Back-Madruga C; Wright EC; Snow KK; Lok AS; Kronfol Z; Padmanabhan L; Hepatology; 2007 May; 45(5):1154-63. PubMed ID: 17465000 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880 [TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553 [TBL] [Abstract][Full Text] [Related]
10. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182 [No Abstract] [Full Text] [Related]
11. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815 [TBL] [Abstract][Full Text] [Related]
12. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases]. Lopukhova NL Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502 [No Abstract] [Full Text] [Related]
14. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection. Shen Y; Pielop J; Hsu S Arch Dermatol; 2005 Jan; 141(1):102-3. PubMed ID: 15655158 [No Abstract] [Full Text] [Related]
15. [Combination therapy for chronic viral hepatitis C]. Zeuzem S Dtsch Med Wochenschr; 2003 Feb; 128(8):370-4. PubMed ID: 12594622 [No Abstract] [Full Text] [Related]
16. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737 [TBL] [Abstract][Full Text] [Related]
17. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C. Yang WS; Chu PL; Liu CH; Chung GB; Wu KD J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301 [No Abstract] [Full Text] [Related]
18. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS; Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661 [TBL] [Abstract][Full Text] [Related]
19. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Lindahl K; Stahle L; Bruchfeld A; Schvarcz R Hepatology; 2005 Feb; 41(2):275-9. PubMed ID: 15660393 [TBL] [Abstract][Full Text] [Related]
20. Interferon for hepatitis C patients with psychiatric disorders. Rifai MA; Bozorg B; Rosenstein DL Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919 [No Abstract] [Full Text] [Related] [Next] [New Search]